Evidence map›Paper›PMID 39797405›Full record

ArticleBritish journal of pharmacology2025

Activation of δ-opioid receptors blocks allodynia in a model of headache induced by PACAP.

Elizaveta Mangutov, Isaac Dripps, Kendra Siegersma, Yanping Zhang, Rebecca Bocian, Sarah Asif, Timothy Halbesma, Wiktor Witkowski, Amynah A Pradhan

Abstract read
In one paragraph

Article in British journal of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. PACAP versus CGRP in migraine: From mouse models to clinical translation.Cephalalgia : an international journal of headache · 2025
    Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elizaveta MangutovCenter for Clinical Pharmacology, Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Isaac DrippsDepartment of Psychiatry, University of Illinois at Chicago, Chicago, Illinois, USA.
Kendra SiegersmaDepartment of Psychiatry, University of Illinois at Chicago, Chicago, Illinois, USA.
Yanping ZhangCenter for Clinical Pharmacology, Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Rebecca BocianDepartment of Psychiatry, University of Illinois at Chicago, Chicago, Illinois, USA.
Sarah AsifDepartment of Psychiatry, University of Illinois at Chicago, Chicago, Illinois, USA.
Timothy HalbesmaDepartment of Psychiatry, University of Illinois at Chicago, Chicago, Illinois, USA.
Wiktor WitkowskiDepartment of Psychiatry, University of Illinois at Chicago, Chicago, Illinois, USA.
Amynah A PradhanCenter for Clinical Pharmacology, Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID https://orcid.org/0000-0001-9691-2976

Funding

Alcohol Research Training in epigenetics and pathophysiology (ARTEP)T32AA026577 · NIAAA · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SUBHASH C. PANDEY · 2019 to 2026
$2.7M
The development of delta opioid receptor agonists for the treatment of opioid withdrawal associated behaviorsUG3DA053094 · NIDA · WASHINGTON UNIVERSITY · PI PRADHAN, AMYNAH AMIR ALI · 2022 to 2022
$2.3M
The role of delta opioid receptors in trigeminovascular painR01NS130882 · NINDS · WASHINGTON UNIVERSITY · PI Amynah Amir Ali Pradhan · 2023 to 2026
$1.9M
NIAAA NIH HHS T32 AA026577NIAAA NIH HHS T32AA026577NIDA NIH HHS UG3 DA053094NIDA NIH HHS UG3DA053094NINDS NIH HHS 5R01NS130882NINDS NIH HHS R01 NS130882
6 · The paper itself

Abstract

background and purposePituitary adenylate cyclase activating polypeptide (PACAP) is a human migraine trigger that is being targeted for migraine. The δ-opioid receptor (δ-receptor) is a novel target for the treatment of migraine, but its mechanism remains unclear. The goals of this study were to develop a mouse PACAP-headache model using clinically significant doses of PACAP; determine the effects of δ-receptor activation in this model; and investigate the co-expression of δ-receptors, PACAP and PACAP-PAC1 receptor. EXPERIMENTAL APPROACH: Cephalic allodynia to low doses of acute and chronic PACAP were tested. A triptan (sumatriptan) and a CGRP receptor antagonist (olcegepant) were tested in this model. The δ-receptor agonist SNC80 was tested in PACAP and CGRP-induced headache models. Expression of PACAP, PAC1, CRLR and δ-receptors was determined using in situ hybridisation. KEY

resultsLow doses of PACAP produced dose-dependent acute and chronic cephalic allodynia, blocked by sumatriptan but not by olcegepant. The PAC1 antagonist (M65) did not inhibit CGRP-induced allodynia. There was moderate co-expression of PAC1 and CRLR transcripts in migraine-related regions. SNC80 blocked PACAP- and CGRP-induced allodynia. There was low co-expression of PACAP and δ-receptors in brain regions measured. However, there was high co-expression of PAC1 and δ-receptors in somatosensory cortex, hippocampus and trigeminal nucleus caudalis. CONCLUSION AND IMPLICATIONS: We developed a translationally significant model of PACAP-induced headache, which was mechanistically distinct from CGRP. Activation of δ-receptors blocked PACAP- and CGRP-induced allodynia, and δ-receptors were highly co-expressed with the PACAP-ergic system. Future studies will examine the functional relationship between δ-receptors and PAC1.

Indexed as

HyperalgesiaMigraine DisordersPituitary Adenylate Cyclase-Activating PolypeptideReceptors, Opioid, deltaAnimalsAzepinesBenzamidesCalcitonin Gene-Related Peptide Receptor AntagonistsDisease Models, AnimalMaleMiceMice, Inbred C57BLPiperazinesQuinazolinesReceptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type ISumatriptan4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-N,N-diethylbenzamideAzepinesBenzamidesCalcitonin Gene-Related Peptide Receptor AntagonistsolcegepantPiperazinesPituitary Adenylate Cyclase-Activating PolypeptideQuinazolinesReceptors, Opioid, deltaReceptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type ISumatriptanheadacheopioidRNAScopetrigeminovascular pain

Identifiers

PMID39797405
PMCPMC12706868

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.